TSPSC AEE Hall Ticket

The growth of the EPS is critical in understanding the current valuation of FireEye. It is usually expressed as a percentage and is then referred to as the EPS growth rate, which is 15.00%. Growth in EPS is an important measure of administration performance because it shows how much money FireEye is making for it’s investors or shareholders.



FireEye is in the application software industry and trades as part of the technology sector. The company CEO is Kevin R. Mandia. FireEye Inc provides cybersecurity solution for detecting, preventing and resolving cyber-attacks that evade legacy signature-based security products. Its solutions include traditional and next-generation firewalls, IPS, anti-virus, and gateways.

Previous Intraday Performance:

The FEYE shares had a previous change of 1.50% which opened at 16.62 and closed at 16.93. It moved to an intraday high of 17.14 and a low of 16.51.

SeekingAlpha:  ConAgra Brands Is A Buy At Current Price – Cramer’s Lightning Round (10/10/18)

Historical Performance:

Over the last five trading days, FEYE shares returned 1.44% and in the past 30 trading days it returned 3.04%. Over three months, it changed 1.01%. In one year it has changed -0.41% and within that year its 52-week high was 19.36 and its 52-week low was 13.40. FEYE stock is 26.34% above its 52 Week Low.

Our calculations result in a 200 day moving average of 16.51 and a 50 day moving average of 16.00. Right now, FEYE stock is trading 2.57% above its 200 day moving average and may be a good opportunity to buy.

SeekingAlpha:  ConAgra Brands Is A Buy At Current Price – Cramer’s Lightning Round (10/10/18)

Liquidity:

The company has a market cap of $3.3b with 195.0m shares outstanding and a float of 182.3m shares. Trading volume was 4,969,083 shares and has experienced an average volume of 4,769,536 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is good.

Earnings:

The last annual reported EPS for FireEye was -1.67 which ended on 31st of December 2017. Based on 4 analyst estimates, the consensus EPS for the next quarter is -0.18.

Below was the last reported quarterly earnings per share:
06-30-2018:  -0.21
03-31-2018:  -0.27
12-31-2017:  -0.21
09-30-2017:  -0.28



Base on our calculations, the intrinsic value per share is 12.19, which means it might overvalued by -38.92%

Indicators Also to Watch:

Based on the latest filings, there is 81.90% of institutional ownership. Short-interest was 21,934,515, which was 11.25% of shares outstanding. The short-interest ratio or days-to-cover ratio was 5.37. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.

I calculated the beta to be 0.43

SeekingAlpha:  Amicus Therapeutics collaborates with University of Pennsylvania to develop AAV gene therapies

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -41.18%, return on assets is -12.23%, profit margin is -36.60%, price-to-sales is 5.38 and price-to-book is 4.93.

Company Score Card:

Results are out of six:
 3  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 2  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here